‚úÖ PHASE 1 ‚Äî /data/gene_star_phenotype.csv
Columns

Gene,RSID,StarAllele,Phenotype

Minimal clinically valid dataset
Gene,RSID,StarAllele,Phenotype
CYP2D6,rs3892097,*4,Poor
CYP2D6,rs1065852,*10,Intermediate
CYP2D6,rs35742686,*3,Poor
CYP2C19,rs4244285,*2,Poor
CYP2C19,rs4986893,*3,Poor
CYP2C19,rs12248560,*17,Rapid
CYP2C9,rs1799853,*2,Intermediate
CYP2C9,rs1057910,*3,Poor
TPMT,rs1800462,*2,Poor
TPMT,rs1142345,*3A,Poor
DPYD,rs3918290,*2A,Poor
DPYD,rs67376798,*13,Poor
SLCO1B1,rs4149056,*5,LowFunction
SLCO1B1,rs2306283,*1B,Normal

Clinical meaning

Poor ‚Üí reduced or absent enzyme activity

Intermediate ‚Üí reduced metabolism

Rapid ‚Üí increased metabolism

LowFunction (SLCO1B1) ‚Üí reduced drug transport

This file enables:
VCF ‚Üí star allele ‚Üí phenotype.

‚úÖ PHASE 2 ‚Äî /data/drug_rules.csv
Columns

Drug,Gene,Phenotype,Risk,Recommendation,Alternative

Core decision rules (aligned with CPIC logic)
CODEINE,CYP2D6,Poor,Ineffective,Avoid,Morphine
CODEINE,CYP2D6,Ultra,Toxic,Avoid,Morphine
CLOPIDOGREL,CYP2C19,Poor,Ineffective,Avoid,Prasugrel
CLOPIDOGREL,CYP2C19,Intermediate,Adjust Dosage,Consider alternative,Prasugrel
WARFARIN,CYP2C9,Poor,Toxic,Reduce Dose,Apixaban
WARFARIN,CYP2C9,Intermediate,Adjust Dosage,Lower starting dose,Apixaban
SIMVASTATIN,SLCO1B1,LowFunction,Toxic,Use lower dose,Pravastatin
AZATHIOPRINE,TPMT,Poor,Toxic,Avoid,Mycophenolate
FLUOROURACIL,DPYD,Poor,Toxic,Avoid,Capecitabine alternative dosing

Risk interpretation standard

Safe ‚Üí normal metabolism
Adjust Dosage ‚Üí altered exposure
Toxic ‚Üí overdose risk
Ineffective ‚Üí drug won‚Äôt work

This file powers the risk classification engine.

‚úÖ PHASE 3 ‚Äî /data/mechanisms.json

Short, mechanistic, judge-friendly explanations.

{
  "CODEINE_CYP2D6": "CYP2D6 converts codeine into active morphine. Poor metabolizers cannot activate the drug; ultra-rapid metabolizers produce excessive morphine causing toxicity.",

  "CLOPIDOGREL_CYP2C19": "CYP2C19 activates clopidogrel. Loss-of-function variants reduce formation of active metabolite leading to reduced antiplatelet effect.",

  "WARFARIN_CYP2C9": "CYP2C9 metabolizes warfarin. Reduced enzyme activity slows drug clearance and increases bleeding risk.",

  "SIMVASTATIN_SLCO1B1": "SLCO1B1 transports simvastatin into hepatocytes. Reduced transport increases systemic drug concentration and muscle toxicity risk.",

  "AZATHIOPRINE_TPMT": "TPMT inactivates thiopurines. Deficiency causes accumulation of toxic metabolites leading to myelosuppression.",

  "FLUOROURACIL_DPYD": "DPYD metabolizes fluorouracil. Deficiency causes severe drug accumulation and life-threatening toxicity."
}


This feeds the LLM with biological grounding.

‚úÖ PHASE 4 ‚Äî VALIDATION CHECKLIST

When backend gives outputs, verify:

Genetic interpretation

‚úî Star allele matches RSID
‚úî Diplotype logically inferred
‚úî Phenotype matches mapping

Clinical decision

‚úî Drug‚Äìgene pairing correct
‚úî Risk label matches phenotype
‚úî Recommendation consistent with guideline

Common failure cases to watch

Wrong gene selected as primary

Normal phenotype labeled toxic

Missing alternative drug

Unknown phenotype misclassified

Report mismatches as:

Patient ID:
Drug:
Expected:
Observed:
Reason:

üßë‚Äç‚öïÔ∏è FINAL PHASE ‚Äî 1-Minute Judge Explanation

Here‚Äôs a clean, professional script you can deliver:

Pharmacogenomics explains why patients respond differently to the same medication. Many drugs are metabolized by enzymes encoded by genes such as CYP2D6 or CYP2C19. Genetic variants can reduce or increase enzyme activity, leading to treatment failure or life-threatening toxicity. Our system analyzes patient genomic variants from standard VCF files, identifies clinically relevant pharmacogenes, predicts metabolic phenotype, and applies evidence-based prescribing guidelines. This allows clinicians to adjust therapy before harm occurs, transforming medication selection from trial-and-error into precision medicine.